

The Cardiac Myosin Inhibitor, CK-3772271, Attenuates Cardiac Fibrosis and Diastolic Dysfunction in the Dahl/Salt Sensitive Rat Model of Heart Failure with Preserved Ejection Fraction

Darren T Hwee, James J Hartman, Jingying Wang, Yangsong Wu, Claire McHugh, Xihui Xu, Eva R Chin, Fady I Malik, Bradley P Morgan

Research and Non-Clinical Development, Cytokinetics, Incorporated, South San Francisco, CA, USA

ABSTRACT

Introduction

Heart failure with preserved ejection fraction (HFpEF) is characterized by abnormal contractility and progressive myocardial fibrosis and stiffness. CK-3772271 (CK-271) is a novel small molecule cardiac myosin inhibitor that reduces cardiac myosin ATPase activity and reduces cardiac contractility in unloaded isolated cardiomyocytes in vitro and in healthy rats and dogs in vivo. The effect of chronic CK-271 treatment on cardiac function and morphology was evaluated in the Dahl/Salt Sensitive (DSS) rat hypertension model of HFpEF.

Methods

DSS male rats were fed either a control low salt (LS, 0.3% NaCl) or high salt (HS, 4% NaCl) diet to induce a hypertension-driven HFpEF disease phenotype. Six weeks after HS diet treatment, DSS rats were randomized into two subgroups: continued HS diet or a HS diet formulated with CK-271 (100 ppm) for an additional 6 weeks. Body mass, systolic blood pressure, and cardiac function were measured longitudinally. After 12 weeks of HS treatment hearts were collected to assess cardiac fibrosis.

Results

HS diet treatment increased systolic blood pressure (LS: 132.2 ± 4.7 mmHg vs HS: 163.5 ± 4.0 mmHg, mean ± standard error of the mean, $p < 0.001$) and caused cardiac hypercontractility as evidenced by an increase in the end-systolic pressure-volume relationship (LS: 0.8 ± 0.17 vs HS: 2.1 ± 0.46 $\mu\text{L}/\text{mmHg}$). HS diet also increased isovolumic relaxation time (IVRT) (LS: 16.8 ± 0.6 vs HS: 22.8 ± 0.6 ms, $p < 0.0001$), left atrial area (LS: 30.3 ± 0.8 vs HS: 42.5 ± 2.2 mm^2 , $p < 0.0001$), and cardiac fibrosis (LS: 3.4 ± 0.4 vs HS: 5.0 ± 0.6%). Six weeks of CK-271 treatment reduced fractional shortening (HS: 53.8 ± 1.4 vs HS + CK-271: 42.7 ± 1.0%, $p < 0.0001$) and reduced HS diet-induced diastolic dysfunction, including IVRT (HS: 22.8 ± 0.6 vs HS + CK-271: 19.5 ± 0.5 ms, $p < 0.0001$) and left atrial area (HS: 42.5 ± 2.2 vs HS + CK-271: 35.4 ± 0.8 mm^2 , $p < 0.0001$). Furthermore, CK-271 reduced the development of cardiac fibrosis (HS: 5.0 ± 0.6 vs HS + CK-271: 3.5 ± 0.3%, $p < 0.05$) induced by HS diet.

Conclusion

The small molecule cardiac myosin inhibitor, CK-3772271, attenuated the development of diastolic dysfunction and fibrosis by normalizing cardiac contractility in the DSS rat model of HFpEF. Cardiac myosin inhibition may be a novel approach to mitigating the development of HFpEF.

INTRODUCTION

- Heart failure with preserved ejection fraction (HFpEF) is by the clinical syndrome of heart failure in the setting of a normal or near normal LVEF. The underlying pathology is varied, but includes abnormal contractility and progressive myocardial fibrosis and stiffness
- CK-3772271 (CK-271) is a novel small molecule cardiac myosin inhibitor that reduces cardiac myosin ATPase activity and reduces cardiac contractility in unloaded isolated cardiomyocytes in vitro and in healthy rats and dogs in vivo
- The effect of chronic CK-271 treatment on cardiac function and morphology was evaluated in the Dahl/Salt Sensitive (DSS) rat hypertension model of HFpEF

METHODS

Preparation of reagents

- Myofibrils were prepared from flash-frozen bovine cardiac, bovine masseter, and rabbit psoas tissue as described in Hwee et al. (2015)¹; bovine cardiac myosin subfragment-1 was prepared as described in Malik et al. (2011)²

ATPase assays

- Steady-state ATPase activity was measured using a pyruvate kinase and lactate dehydrogenase-coupled enzyme system as described in Hwee et al. (2015)¹ and Malik et al. (2011)². Nonmyosin ATPase activity was subtracted from cardiac and slow skeletal myofibril assays (where indicated) by subtracting the ATPase activity in the presence of a saturating concentration of the nonselective myosin II inhibitor blebbistatin

Measure of cardiomyocyte contractility and calcium transients

- Adult rat ventricular cardiomyocytes were isolated and loaded with fura-2 as described in Malik et al. (2011)². Cardiomyocyte contractility and calcium transients were measured by edge-detection video microscopy and fluorescence photometry (IonOptix, Milton, MA) as described in Malik et al. (2011)²

Evaluation of CK-271 treatment in Dahl/Salt Sensitive (DSS) rats

- 10–11-week-old, DSS male rats were fed either a control low salt (LS, 0.3% NaCl) or high salt (HS, 4% NaCl) diet to induce a hypertension-driven disease phenotype
- After 6 weeks of HS diet treatment, DSS rats were randomized based on body weight and systolic blood pressure into two subgroups: continued HS diet or a HS diet formulated with CK-271 (100 ppm) for an additional 6 weeks
- Systolic blood pressure was measured by tail cuff and cardiac function was assessed by echocardiography and invasive hemodynamics
- After 12 weeks of HS treatment hearts were collected to assess cardiac fibrosis by Masson's trichrome stain

RESULTS

Figure 1. CK-271 inhibits the ATPase activity of bovine cardiac myofibrils and purified bovine cardiac subfragment-1




Figure 3. A 4% high salt (HS) diet increased systolic blood pressure and the end systolic pressure volume relationship in DSS rats




Figure 4. Six weeks of CK-271 treatment reduced fractional shortening in high salt diet-fed DSS rats




Figure 2. CK-271 decreases shortening of isolated adult rat ventricular myocytes without altering Ca^{2+} transients




Figure 5. Six weeks of CK-271 treatment reduced measures of high salt diet-induced diastolic dysfunction





Figure 6. Six weeks of CK-271 treatment reduced the development of cardiac fibrosis in DSS rats



CONCLUSIONS

- CK-3772271 is a novel small molecule that selectively inhibits cardiac myosin ATPase activity and contractility in vitro
- CK-3772271 attenuated the development of cardiac hypercontractility, diastolic dysfunction, and fibrosis in the DSS rat model of HFpEF
- Cardiac myosin inhibition may be a viable approach to address hypercontractility and associated hemodynamic and subsequent cardiac structural abnormalities associated with HF

References

- Hwee et al. (2015). *J Pharmacol Exp Ther*. 353(1):159–168.
- Malik et al. (2011). *Science*. 331(6023):1439–1443.

Acknowledgments

This study was funded by Cytokinetics, Incorporated. Editorial support was provided by Richard Fay, PhD, CMPP on behalf of Evidence Scientific Solutions, Philadelphia, PA, and was funded by Cytokinetics, Incorporated.

Disclosures

All authors are current or former employees of Cytokinetics, Incorporated and were financially compensated for their work.